Brokerages Set Agile Therapeutics Inc (NASDAQ:AGRX) Target Price at $4.00

Agile Therapeutics Inc (NASDAQ:AGRX) has been given a consensus rating of “Buy” by the six analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $3.50.

Several research firms have issued reports on AGRX. Maxim Group set a $3.00 price target on Agile Therapeutics and gave the company a “buy” rating in a research note on Friday, October 11th. Zacks Investment Research raised Agile Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research note on Tuesday. Finally, ValuEngine downgraded Agile Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 2nd.

AGRX opened at $1.19 on Friday. The business’s 50-day moving average price is $1.20 and its two-hundred day moving average price is $1.29. Agile Therapeutics has a 1 year low of $0.53 and a 1 year high of $1.70. The company has a market capitalization of $55.07 million, a price-to-earnings ratio of -2.05 and a beta of 0.38.

Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings results on Thursday, August 1st. The specialty pharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.03. Research analysts expect that Agile Therapeutics will post -0.37 EPS for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its stake in shares of Agile Therapeutics by 2,219.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 76,538 shares of the specialty pharmaceutical company’s stock valued at $108,000 after purchasing an additional 73,238 shares during the period. BlackRock Inc. grew its holdings in shares of Agile Therapeutics by 27.2% in the 2nd quarter. BlackRock Inc. now owns 169,226 shares of the specialty pharmaceutical company’s stock valued at $247,000 after acquiring an additional 36,212 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Agile Therapeutics by 7.9% in the 2nd quarter. Acadian Asset Management LLC now owns 450,180 shares of the specialty pharmaceutical company’s stock valued at $657,000 after acquiring an additional 32,911 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Agile Therapeutics by 129.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,732,648 shares of the specialty pharmaceutical company’s stock valued at $2,530,000 after acquiring an additional 978,672 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Agile Therapeutics by 5.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,254,180 shares of the specialty pharmaceutical company’s stock valued at $3,291,000 after acquiring an additional 120,403 shares in the last quarter. 43.77% of the stock is currently owned by hedge funds and other institutional investors.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.

Featured Story: If I purchase shares through a brokerage account, am I the holder of record?

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.